AU2021350581A1 - Extended release pharmaceutical formulation - Google Patents

Extended release pharmaceutical formulation Download PDF

Info

Publication number
AU2021350581A1
AU2021350581A1 AU2021350581A AU2021350581A AU2021350581A1 AU 2021350581 A1 AU2021350581 A1 AU 2021350581A1 AU 2021350581 A AU2021350581 A AU 2021350581A AU 2021350581 A AU2021350581 A AU 2021350581A AU 2021350581 A1 AU2021350581 A1 AU 2021350581A1
Authority
AU
Australia
Prior art keywords
tablet
ketamine
active agent
molecular weight
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021350581A
Other languages
English (en)
Inventor
Paul William Glue
Yuefeng Long
Natalie June Medlicott
Peter William Surman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Douglas Pharmaceuticals Ltd
Original Assignee
Douglas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/030,705 external-priority patent/US12090123B2/en
Application filed by Douglas Pharmaceuticals Ltd filed Critical Douglas Pharmaceuticals Ltd
Publication of AU2021350581A1 publication Critical patent/AU2021350581A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2021350581A 2020-09-24 2021-09-22 Extended release pharmaceutical formulation Pending AU2021350581A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/030,705 2020-09-24
US17/030,705 US12090123B2 (en) 2017-10-10 2020-09-24 Extended release pharmaceutical formulation
PCT/IB2021/058647 WO2022064387A1 (en) 2020-09-24 2021-09-22 Extended release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
AU2021350581A1 true AU2021350581A1 (en) 2023-03-23

Family

ID=80846364

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021350581A Pending AU2021350581A1 (en) 2020-09-24 2021-09-22 Extended release pharmaceutical formulation

Country Status (9)

Country Link
US (1) US20250049734A1 (https=)
EP (1) EP4216937A4 (https=)
JP (1) JP2023543211A (https=)
KR (1) KR20230074522A (https=)
CN (1) CN116456972A (https=)
AU (1) AU2021350581A1 (https=)
CA (1) CA3190204A1 (https=)
MX (1) MX2023003369A (https=)
WO (1) WO2022064387A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869838B2 (en) * 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
WO2024171074A1 (en) * 2023-02-15 2024-08-22 Clearmind Medicine Inc. Compositions comprising ketamine, optionally in combination with n-acylethanolamines, and uses thereof
WO2025099182A1 (en) * 2023-11-07 2025-05-15 HMNC Holding GmbH Induction regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one
WO2025099181A1 (en) * 2023-11-07 2025-05-15 HMNC Holding GmbH Maintenance regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922507C (en) * 2013-08-26 2022-07-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
DK3215147T3 (da) * 2014-11-04 2024-04-02 Acadia Pharm Inc Neurodæmpende norketamin-forbindelser og fremgangsmåder
US10441544B2 (en) * 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
CN111630026A (zh) * 2017-10-10 2020-09-04 道格拉斯制药有限公司 缓释药物制剂和治疗方法

Also Published As

Publication number Publication date
EP4216937A4 (en) 2024-09-04
WO2022064387A1 (en) 2022-03-31
CA3190204A1 (en) 2022-03-31
EP4216937A1 (en) 2023-08-02
JP2023543211A (ja) 2023-10-13
MX2023003369A (es) 2023-08-14
KR20230074522A (ko) 2023-05-30
US20250049734A1 (en) 2025-02-13
CN116456972A (zh) 2023-07-18

Similar Documents

Publication Publication Date Title
US11045424B2 (en) Extended release pharmaceutical formulation
US12350378B2 (en) Extended release pharmaceutical formulation and methods of treatment
US12472146B2 (en) Extended release pharmaceutical formulation
US11471416B2 (en) Extended release pharmaceutical formulation and methods of treatment
US12611386B2 (en) Extended release pharmaceutical formulation
US20250049734A1 (en) Extended release pharmaceutical formulation
US20260034065A1 (en) Extended release pharmaceutical formulation
HK40066605B (en) Extended release pharmaceutical formulation
HK40066605A (en) Extended release pharmaceutical formulation

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GLUE, PAUL WILLIAM; MEDLICOTT, NATALIE JUNE; SURMAN, PETER WILLIAM AND LONG, YUEFENG